Valuation: BLS Pharmaceuticals Limited

Market Cap 229M 160M 141M 133M 121M 227M 15.34B 1.6B 617M 7.83B 600M 587M 25.2B P/E 2025
17.8x
P/E 2026 13.9x
Enterprise Value 224M 156M 138M 131M 118M 222M 15.01B 1.57B 604M 7.67B 587M 575M 24.67B EV / Sales 2025
2.82x
EV / Sales 2026 2.82x
Free-Float
41.59%
Yield 2025 *
-
Yield 2026 -
1 day+5.53%
1 week-9.09%
Current month-0.94%
1 month-0.94%
3 months+12.90%
6 months+84.21%
Current year+150.00%
1 week 0.94
Extreme 0.945
1.15
1 month 0.93
Extreme 0.93
1.3
Current year 0.36
Extreme 0.36
1.3
1 year 0.33
Extreme 0.33
1.3
3 years 0.04
Extreme 0.04
1.3
5 years 0.04
Extreme 0.04
1.3
10 years 0.04
Extreme 0.04
1.4
Manager TitleAgeSince
Chief Executive Officer - 2023-05-18
Director of Finance/CFO 72 2016-08-31
Chief Operating Officer - -
Director TitleAgeSince
Chairman 67 2012-12-04
Director/Board Member 72 2022-06-29
Director/Board Member - 2023-05-18
Date Insider Type Main position Quantity % Market Cap. Importance
5/14/26 Buy 5,000,000 0.2202%
5/14/26 Exercice 5,000,000 0.2202%
3/22/26 Buy

Chief Executive Officer

1,800,000 0.0804%
Change 5-day change 1-year change 3-year change Capi.($)
+5.53%-9.09%+176.32%+854.55% 160M
-0.29%+3.49%+10.28%+38.26% 48.85B
-0.73%-0.41%+48.84%+36.72% 44.28B
+1.36%+6.03%+343.85%+638.73% 43.83B
-0.47%-0.76%+9.75%+103.07% 41.53B
+0.34%+0.22%+5.18%+47.36% 30.13B
+1.00%-1.28%+24.23%+156.93% 17.36B
-0.73%-0.68%+22.43%+44.52% 14.99B
-2.94%+6.98%+5.10% - 14.9B
-0.86%-4.00% - - 14.98B
Average +0.51%-1.02%+71.78%+240.02% 27.1B
Weighted average by Cap. -0.01%+1.20%+74.82%+168.89%

Financials

2025 2026
Net sales 29.28M 20.42M 18.02M 17.05M 15.47M 28.99M 1.96B 205M 78.84M 1B 76.69M 75.02M 3.22B 73.91M 51.55M 45.49M 43.04M 39.04M 73.19M 4.95B 516M 199M 2.53B 194M 189M 8.13B
Net income 4.9M 3.42M 3.02M 2.85M 2.59M 4.85M 328M 34.24M 13.2M 168M 12.84M 12.56M 539M 15.4M 10.74M 9.48M 8.97M 8.13M 15.25M 1.03B 108M 41.46M 526M 40.33M 39.45M 1.69B
Net Debt -6.13M -4.28M -3.78M -3.57M -3.24M -6.07M -411M -42.86M -16.52M -210M -16.07M -15.72M -675M -4.86M -3.39M -2.99M -2.83M -2.56M -4.81M -325M -33.93M -13.08M -166M -12.72M -12.44M -534M
Logo BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Employees
-
Date Price Change Volume
26-09-30 A$1.050 +5.53% 210,245
26-09-29 A$0.9950 -1.97% 584,377
26-09-28 A$1.015 -1.46% 817,109
26-09-25 A$1.030 -2.83% 701,683
26-09-24 A$1.060 -8.23% 1,619,547

Annual profits - Rate of surprise